Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
Wuerstlein R, Kates R, Gluz O, Grischke EM, Schem C, Thill M, Hasmueller S, Köhler A, Otremba B, Griesinger F, Schindlbeck C, Trojan A, Otto F, Knauer M, Pusch R, Harbeck N; WSG-PRIMe investigators in Germany, Austria, Switzerland.
Wuerstlein R, et al. Among authors: harbeck n.
Breast Cancer Res Treat. 2019 Jun;175(2):389-399. doi: 10.1007/s10549-018-05075-x. Epub 2019 Feb 22.
Breast Cancer Res Treat. 2019.
PMID: 30796651
Free PMC article.
Clinical Trial.